Ultragenyx Alert for Shareholders: Important Deadline for Class Action Lawsuit

Important Alert for Ultragenyx Shareholders

Are you an investor in Ultragenyx Pharmaceutical Inc. who has experienced significant financial losses? If so, it’s crucial to be aware of a pending class action lawsuit against the company and the deadlines that could affect your ability to seek restitution. ClaimsFiler has issued a reminder that shareholders who incurred losses exceeding $100,000 have until April 6, 2026, to file their lead plaintiff applications.

Background on the Situation

The class action lawsuit is targeted at Ultragenyx, and it specifically involves claims that the company and certain executives failed to disclose essential information regarding its operations during a defined period. This class action lawsuit concerns those who acquired shares from August 3, 2023, to December 26, 2025. Notably, on December 26, 2025, Ultragenyx disclosed negative results from its Phase 3 Orbit and Cosmic studies related to their product setrusumab (UX143), which was being evaluated for treating Osteogenesis Imperfecta. The results showed no statistically significant reduction in fracture rates, which led to a dramatic decrease in the company’s stock price—approximately 42%—over a brief period.

The stock’s decline from $34.19 per share to $19.72 on December 29, 2025, is raising concerns among investors, prompting action from shareholder advocacy services like ClaimsFiler.

Legal Proceedings

The case at hand is officially titled Steven Bailey v. Ultragenyx Pharmaceutical Inc., et al., bearing the number No. 26-cv-01097 and is filed in the United States District Court for the Southern District of New York. Investors who purchased or otherwise acquired shares during the specified Class Period may want to act quickly to secure their position in any potential settlement that may be reached depending on the lawsuit’s outcome.

ClaimsFiler offers resources for investors who wish to learn more about their legal options regarding this situation. Interested shareholders can access their free services by visiting ClaimsFiler.com or contacting their office at the toll-free number 844-367-9658. Their qualified legal partners, Kahn Swick & Foti, LLC, are ready to assist with inquiries.

What ClaimsFiler Offers

ClaimsFiler has established itself as a trusted information source for retail investors, providing tools to help recover losses from securities class action settlements. Features include:
1. Access to Information: Shareholders can register for free to receive updates on relevant securities class action cases and deadlines.
2. Portfolio Tracking: Investors can upload their transactional data to get notifications about cases that might affect their financial interests.
3. Legal Consultation: For free case evaluations, shareholders can reach out to the law firm associated with ClaimsFiler.

Conclusion

For Ultragenyx investors, the clock is ticking. The upcoming deadline on April 6, 2026, is your chance to possibly reclaim some of your investments. Knowledge is power, so accessing the resources provided by ClaimsFiler could put you on a path towards recovering losses during these turbulent times. Make sure you stay informed and take action before it's too late!